Literature DB >> 15105158

Novel inhalational murine model of invasive pulmonary aspergillosis.

Donald C Sheppard1, Gunter Rieg, Lisa Y Chiang, Scott G Filler, John E Edwards, Ashraf S Ibrahim.   

Abstract

We developed a novel model of invasive aspergillosis (IA) that recapitulates human disease. Mice were immunosuppressed with cyclophosphamide and cortisone acetate and then infected in an aerosol chamber. This procedure reproducibly delivered 1 x 10(3) to 3 x 10(3) conidia to the lungs. Lethal pulmonary IA developed over 2 weeks and was prevented by amphotericin B.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105158      PMCID： PMC400587          DOI： 10.1128/AAC.48.5.1908-1911.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.

Authors:  D W Denning; A Marinus; J Cohen; D Spence; R Herbrecht; L Pagano; C Kibbler; V Kcrmery; F Offner; C Cordonnier; U Jehn; M Ellis; L Collette; R Sylvester
Journal:  J Infect       Date:  1998-09       Impact factor: 6.072

Review 3.  Therapeutic outcome in invasive aspergillosis.

Authors:  D W Denning
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

4.  Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.

Authors:  Ryogo Hayashi; Naomi Kitamoto; Yuji Iizawa; Takashi Ichikawa; Katsumi Itoh; Tomoyuki Kitazaki; Kenji Okonogi
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

Authors:  A H Groll; P M Shah; C Mentzel; M Schneider; G Just-Nuebling; K Huebner
Journal:  J Infect       Date:  1996-07       Impact factor: 6.072

8.  Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.

Authors:  Brad Spellberg; Douglas Johnston; Quynh Trang Phan; John E Edwards; Samuel W French; Ashraf S Ibrahim; Scott G Filler
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis.

Authors:  P G Pal; M A Horwitz
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

10.  SCH56592 treatment of murine invasive aspergillosis.

Authors:  J R Graybill; R Bocanegra; L K Najvar; M F Luther; D Loebenberg
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790
  10 in total
  76 in total

1.  Pulmonary injury after combined exposures to low-dose low-LET radiation and fungal spores.

Authors:  B Marples; L Downing; K E Sawarynski; J N Finkelstein; J P Williams; A A Martinez; G D Wilson; M D Sims
Journal:  Radiat Res       Date:  2011-01-28       Impact factor: 2.841

2.  Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.

Authors:  Martina Lengerova; Iva Kocmanova; Zdenek Racil; Kristyna Hrncirova; Sarka Pospisilova; Jiri Mayer; Laura K Najvar; Nathan P Wiederhold; William R Kirkpatrick; Thomas F Patterson
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

3.  The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Authors:  Brad J Spellberg; Ashraf S Ibrahim; Valentina Avenissian; Scott G Filler; Carter L Myers; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Microbial glycoside hydrolases as antibiofilm agents with cross-kingdom activity.

Authors:  Brendan D Snarr; Perrin Baker; Natalie C Bamford; Yukiko Sato; Hong Liu; Mélanie Lehoux; Fabrice N Gravelat; Hanna Ostapska; Shane R Baistrocchi; Robert P Cerone; Elan E Filler; Matthew R Parsek; Scott G Filler; P Lynne Howell; Donald C Sheppard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-20       Impact factor: 11.205

5.  Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.

Authors:  Gunter Rieg; Brad Spellberg; Julie Schwartz; Yue Fu; John E Edwards; Donald C Sheppard; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  Standardization of an experimental murine model of invasive pulmonary aspergillosis.

Authors:  Donald C Sheppard; John R Graybill; Laura K Najvar; Lisa Y Chiang; Thomas Doedt; William R Kirkpatrick; Rosie Bocanegra; Ana C Vallor; Thomas F Patterson; Scott G Filler
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

7.  The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy.

Authors:  Shane D Stephens-Romero; Aron J Mednick; Marta Feldmesser
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  Assessment of serum (1->3)-beta-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Ana C Vallor; William R Kirkpatrick; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

9.  Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.

Authors:  Justin A Tolman; Nathan P Wiederhold; Jason T McConville; Laura K Najvar; Rosie Bocanegra; Jay I Peters; Jacqueline J Coalson; John R Graybill; Thomas F Patterson; Robert O Williams
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

10.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.